17.04.2020 | ASO Author Reflections
ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases
verfasst von:
Joel M. Baumgartner, MD, MAS, Paul Riviere, BS, Razelle Kurzrock, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2020
Einloggen, um Zugang zu erhalten
Excerpt
The peritoneum is a potential site of metastasis in virtually all pelvic and abdominal malignancies. Surgical treatment with debulking or complete cytoreduction with or without hyperthermic intraperitoneal chemotherapy (HIPEC) can provide palliation of symptoms and, potentially, survival advantages over other treatments; however, radiographic identification of residual or recurrent peritoneal disease is challenging.
1,
2 A biomarker that could identify residual or recurrent disease might provide improved postoperative risk stratification and surveillance assessments. Cell-free circulating tumor DNA (ctDNA) shed from tumor is measurable in plasma and provides both quantitative and qualitative data that can be assessed non-invasively over time. We have previously found that ctDNA liquid biopsy is a preoperative prognosticator after surgical resection of peritoneal metastases,
3 but questions remain about its utility for risk stratification and surveillance in the postoperative setting. …